Zenas BioPharma (ZBIO) Short-term Investments (2024 - 2026)

Zenas BioPharma's Short-term Investments history runs 3 years deep, the most recent figure standing at $217.0 million for Q1 2026.

• On a quarterly basis, Short-term Investments rose 87.34% year-over-year to $217.0 million in Q1 2026; TTM through Mar 2026 was $217.0 million, a 87.34% increase from a year earlier, with the FY2025 full-year figure at $232.6 million, up 649.58% from the prior year.
• Short-term Investments slipped to $217.0 million in Q1 2026 per ZBIO's latest filing, from $232.6 million in the prior quarter.
• Across five years, Short-term Investments topped out at $232.6 million in Q4 2025 and bottomed at $86000.0 in Q1 2024.
• The 3-year median for Short-term Investments is $115.8 million (2025), against an average of $111.2 million.
• Across the five-year window, Short-term Investments soared 260437.5% in 2025 and soared 87.34% in 2026, its largest moves.
• Year by year, Short-term Investments stood at $31.0 million in 2024, then surged by 649.58% to $232.6 million in 2025, then dropped by 6.7% to $217.0 million in 2026.
• Per Business Quant, the three latest ZBIO Short-term Investments figures stand at $217.0 million (Q1 2026), $232.6 million (Q4 2025), and $175.3 million (Q3 2025).